MGX: Investor Sentiment and Bull/Bear Views
Metagenomi Therapeutics, Inc. Common Stock
Loading...
Loading...
Buzzberg insights
Attention & activity
- unique authors
- 1
- vs usual
- New
24h1
30d avg / day0
- unique authors
- 1
- vs usual
- New
7d1
4wk avg / week0
Author calls
What authors recommend
- Long
- 100.0%Authors: 1
- Short
- 0.0%Authors: 0
- Avoid
- 0.0%Authors: 0
- Long
- 100.0%Authors: 1
- Short
- 0.0%Authors: 0
- Avoid
- 0.0%Authors: 0
Author positions
What authors disclose
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
Feed & authors
- ideas
- 4
- Authors
- 2
- Sources
- 2
Call performance
Performance since each author’s call.
| Author | Direction | Return |
|---|---|---|
| No data yet | ||
Best calls over the past year · return since each call
Company facts
- Market cap
- $25.71M 2026-11-16
Financial results are not available yet.
Financial details
Market cap · polygon · 2026-11-16
Sentiment
Attention
1Newvs usual
unique authors
30d avg / day 0
Attention
1Newvs usual
unique authors
4wk avg / week 0
Loading chart...
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
16:06
Nov 17
Nov 17
r/biotech_stocks
Reddit
Small speculative MGX long on FDA clearance, MGX-001
The author thinks a small speculative position in MGX around $0.70 could be worth considering because FDA clearance and the potential of MGX-001 make the risk/reward interesting. The author concedes dilution risk is likely higher than the headline runway suggests and that human data in H2 2027 is the real test. ASH is viewed as an interesting near-term sentiment catalyst rather than proof. Main stated risks are further dilution and clinical setbacks.